Post hoc analysis of the phase 2 LILAC trial in adults with cutaneous lupus erythematosus: at week 16 more litifilimab than placebo recipients reached CLASI-20/50/70/90 responses (3.8%-72.1% vs 0%-43.8%) and clear or almost clear skin.
Secondary analysis
Werth et al. Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study